Tenax Story

<div class='circular--portrait' style='background:#8B008B;color: #ffffff;font-size:4em;'>TT</div>
TENX -- USA Stock  

USD 1.11  0.12  9.76%

Today's article will break down Tenax Therapeutics. I will take a closer look at this stock and the current sentiment generated by investors. This post is to show some fundamental factors affecting Tenax Therapeutics' products and services. I will also show how it may impact the investing outlook for the firm in December.
Published over two weeks ago
View all stories for Tenax Therapeutics | View All Stories
Should you hold on to your Tenax Therapeutics position?
About 40.0% of Tenax Therapeutics shares are owned by institutional investors. Insiders ownership of Tenax Therapeutics refers to the amount of Tenax Therapeutics equity owned by Tenax officers, directors, relatives of the leadership team, or anyone who has access to private information before it's made available to the public. Check out our latest analysis of Tenax, including its current ownership diagnostics.

Watch out for price decline

Please consider monitoring Tenax Therapeutics on a daily basis if you are holding a position in it. Tenax Therapeutics is trading at a penny-stock level, and the possibility of delisting is much higher compared to other equities. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as Tenax Therapeutics stock to be traded above the $1 level to remain listed. If Tenax Therapeutics stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.

How important is Tenax Therapeutics's Liquidity

Tenax Therapeutics financial leverage refers to using borrowed capital as a funding source to finance Tenax Therapeutics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Tenax Therapeutics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Tenax Therapeutics's total debt and its cash.

How Tenax utilizes its cash?

To perform a cash flow analysis of Tenax Therapeutics, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Tenax Therapeutics is receiving and how much cash it distributes out in a given period. The Tenax Therapeutics cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.

Purchase by Armistice Capital Llc of tradable shares of Tenax Therapeutics

Legal trades by Tenax Therapeutics insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Tenax insider trading alert for perchase of common stock by Armistice Capital Llc, the corporate stakeholder, on 9th of September 2020. This event was filed by Tenax Therapeutics Inc with SEC on 2020-09-09. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.


Tenax Therapeutics maintains a total of 12.62 Million outstanding shares. 30% of Tenax Therapeutics outstanding shares are owned by institutional holders. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulation than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or about to change. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Ownership Breakdown

Retail Investors
Retail Investors59.96

Tenax Therapeutics price slide is puzzling

Tenax Therapeutics current standard deviation rises over 5.62. Tenax Therapeutics exhibits very low volatility with skewness of -0.69 and kurtosis of 3.43. However, we advise investors to further study Tenax Therapeutics technical indicators to make sure all market info is available and is reliable. Tenax Therapeutics is a potential penny stock. Although Tenax Therapeutics may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Tenax Therapeutics. We encourage investors to look for the signals such us email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on this equity instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of an artificial hype usually unable to maintain its increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.

Our Final Take On Tenax Therapeutics

While some firms in the biotechnology industry are either recovering or due for a correction, Tenax may not be as strong as the others in terms of longer-term growth potentials. The inconsistency in the assessment between current Tenax valuation and our trade advice on Tenax Therapeutics is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Tenax Therapeutics.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of Tenax Therapeutics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com